Last reviewed · How we verify
KX2-391 and Paclitaxel
KX2-391 and Paclitaxel is a Small molecule drug developed by Hanmi Pharmaceutical Company Limited. It is currently in Phase 1 development. Also known as: KX01, Taxol.
At a glance
| Generic name | KX2-391 and Paclitaxel |
|---|---|
| Also known as | KX01, Taxol |
| Sponsor | Hanmi Pharmaceutical Company Limited |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Study of KX2-391 With Paclitaxel in Patients With Solid Tumors (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- KX2-391 and Paclitaxel CI brief — competitive landscape report
- KX2-391 and Paclitaxel updates RSS · CI watch RSS
- Hanmi Pharmaceutical Company Limited portfolio CI
Frequently asked questions about KX2-391 and Paclitaxel
What is KX2-391 and Paclitaxel?
KX2-391 and Paclitaxel is a Small molecule drug developed by Hanmi Pharmaceutical Company Limited.
Who makes KX2-391 and Paclitaxel?
KX2-391 and Paclitaxel is developed by Hanmi Pharmaceutical Company Limited (see full Hanmi Pharmaceutical Company Limited pipeline at /company/hanmi-pharmaceutical-company-limited).
Is KX2-391 and Paclitaxel also known as anything else?
KX2-391 and Paclitaxel is also known as KX01, Taxol.
What development phase is KX2-391 and Paclitaxel in?
KX2-391 and Paclitaxel is in Phase 1.
Related
- Manufacturer: Hanmi Pharmaceutical Company Limited — full pipeline
- Also known as: KX01, Taxol
- Compare: KX2-391 and Paclitaxel vs similar drugs
- Pricing: KX2-391 and Paclitaxel cost, discount & access